Various rates of Streptococcus pneumoniae with diminished susceptibility to Penicillin G (PNSP) are reported worldwide, while resistance to cefotaxime and ceftriaxone is actually increasing among S. pneumoniae. The aim of this survey was to determine the evolution of the susceptibility and resistance of S. pneumoniae at our hospital, throughout the years 1997-2004. 582 S. pneumoniae strains, isolated from different patients with pulmonary disease, otitis media, bacteremia and/or meningitis have been observed. MIC to benzylpenicillin (P), ampicillin (AMP) and ceftriaxone (CRO) were determined by E-TEST. Susceptibility to erythromycin (ERY), cotrimoxazole (SXT), tetracycline (TE) and rifampicin (RA) were determined by agar diffusion. All tests were interpreted according to CA-SFM guidelines. The percentage of PNSP varied between 49.6 and 69%. S. pneumoniae with reduced susceptibility to benzylpenicillin had stable rates, while fully resistant S. pneumoniae decreased significantly. Resistance to ampicillin varied alongside with penicillin with a decrease of fully resistant S. pneumoniae. Strains intermediate to ceftriaxone also decreased significantly while those fully resistant were not detected, except for 1999 (1 strain). The resistance (I+R) to SXT and TE remained stable with small variations, but resistance to ERY increased up to 43% of isolated strains in 2004. Resistance to LVX and RA was absent, with unexpected levels for RA (1 and 5%) in 2002 and 2003.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.patbio.2006.07.019DOI Listing

Publication Analysis

Top Keywords

fully resistant
12
pneumoniae
8
streptococcus pneumoniae
8
pneumoniae strains
8
resistant pneumoniae
8
resistance
7
[evolution antibiotic
4
antibiotic resistance
4
resistance streptococcus
4
pneumoniae 1997
4

Similar Publications

Despite advances in healthcare, bacterial pathogens remain a severe global health threat, exacerbated by rising antibiotic resistance. Lower respiratory tract infections, with their high death toll, are of particular concern. Accurately replicating host-pathogen interactions in laboratory models is crucial for understanding these diseases and evaluating new therapies.

View Article and Find Full Text PDF

While the role of cancer stem cells (CSCs) in tumorigenesis, chemoresistance, metastasis, and relapse has been extensively studied in solid tumors, such as adenocarcinomas or sarcomas, the same cannot be said for neuroendocrine neoplasms (NENs). While lagging, CSCs have been described in numerous NENs, including gastrointestinal and pancreatic NENs (PanNENs), and they have been found to play critical roles in tumor initiation, progression, and treatment resistance. However, it seems that there is still skepticism regarding the role of CSCs in NENs, even in light of studies that support the CSC model in these tumors and the therapeutic benefits of targeting them.

View Article and Find Full Text PDF

Objectives: Prostate cancer (PCa) is a leading cause of cancer death in men worldwide. Approximately 30% of castrate-resistant PCa becomes refractory to therapy due to neuroendocrine differentiation (NED) that is present in <1% of de-novo tumors. First-in-class imipridone ONC201/TIC10 therapy has shown clinical activity against midline gliomas, neuroendocrine tumors, and PCa.

View Article and Find Full Text PDF

Bee venom (BV) represents a promising natural alternative to conventional antibiotics, particularly significant given its broad-spectrum antimicrobial activity and potential to address the growing challenge of antimicrobial resistance. The prevalence of antimicrobial-resistant microorganisms (AMR) is a global burden that affects human health and the economies of different countries. As a result, several scientific communities around the world are searching for safe alternatives to antibiotics.

View Article and Find Full Text PDF

In the tumour microenvironment, IL-1α promotes neoangiogenesis, matrix remodelling, tumour proliferation, chemoresistance, and metastases. Highly expressed in human colorectal cancers, IL-1α is associated with poor prognosis. XB2001, a fully human monoclonal antibody neutralizing IL-1α, was evaluated for safety and preliminary efficacy with trifluridine/tipiracil (FTD/TPI) and bevacizumab in metastatic colorectal cancer patients previously treated with oxaliplatin- and irinotecan-based chemotherapies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!